Literature DB >> 10634938

High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences.

G A Francis1.   

Abstract

Elevated levels of plasma high density lipoprotein (HDL) are strongly predictive of protection against atherosclerotic vascular disease. HDL particles likely have several beneficial actions in vivo, including the initiation of reverse cholesterol transport. The apparent importance of oxidative modification of low density lipoprotein in atherogenesis raises the question of how oxidative modification of HDL might affect its cardioprotective actions. HDL is readily oxidized using numerous models of lipoprotein oxidation. In vitro evidence suggests oxidation might impair some protective actions, but actually enhance other mechanisms induced by HDL that prevent the accumulation of cholesterol in the artery wall. This article reviews the current literature concerning the relative oxidizability of HDL, the structural changes induced in HDL by oxidation in vitro, and the potential consequences of oxidative modification on the protective actions of HDL in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10634938     DOI: 10.1016/s1388-1981(99)00181-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

1.  oxHDL decreases the expression of CD36 on human macrophages through PPARgamma and p38 MAP kinase dependent mechanisms.

Authors:  Jingyi Ren; Wenying Jin; Hong Chen
Journal:  Mol Cell Biochem       Date:  2010-05-11       Impact factor: 3.396

2.  Serum amyloid A in uremic HDL promotes inflammation.

Authors:  Thomas Weichhart; Chantal Kopecky; Markus Kubicek; Michael Haidinger; Dominik Döller; Karl Katholnig; Cacang Suarna; Philipp Eller; Markus Tölle; Christopher Gerner; Gerhard J Zlabinger; Markus van der Giet; Walter H Hörl; Roland Stocker; Marcus D Säemann
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

3.  Oxidized high-density lipoprotein impairs endothelial progenitor cells' function by activation of CD36-MAPK-TSP-1 pathways.

Authors:  Jianxiang Wu; Zhiqing He; Xiang Gao; Feng Wu; Ru Ding; Yusheng Ren; Qijun Jiang; Min Fan; Chun Liang; Zonggui Wu
Journal:  Antioxid Redox Signal       Date:  2014-12-02       Impact factor: 8.401

Review 4.  Proteomics investigations of HDL: challenges and promise.

Authors:  Tomáš Vaisar
Journal:  Curr Vasc Pharmacol       Date:  2012-07       Impact factor: 2.719

5.  The Application of Multiple Reaction Monitoring to Assess Apo A-I Methionine Oxidations in Diabetes and Cardiovascular Disease.

Authors:  Hussein N Yassine; Angela M Jackson; Peter D Reaven; Dobrin Nedelkov; Randall W Nelson; Serrine S Lau; Christoph H Borchers
Journal:  Transl Proteom       Date:  2014-12-01

Review 6.  Oxidative risk for atherothrombotic cardiovascular disease.

Authors:  Jane A Leopold; Joseph Loscalzo
Journal:  Free Radic Biol Med       Date:  2009-09-12       Impact factor: 7.376

Review 7.  Lipid peroxidation and decomposition--conflicting roles in plaque vulnerability and stability.

Authors:  Sampath Parthasarathy; Dmitry Litvinov; Krithika Selvarajan; Mahdi Garelnabi
Journal:  Biochim Biophys Acta       Date:  2008-03-25

8.  Oxidized high-density lipoprotein is associated with increased plasma glucose in non-diabetic dyslipidemic subjects.

Authors:  Kazuhiko Kotani; Naoki Sakane; Masashi Ueda; Shinichi Mashiba; Yasuyuki Hayase; Kokoro Tsuzaki; Toshiyuki Yamada; Alan T Remaley
Journal:  Clin Chim Acta       Date:  2012-09-06       Impact factor: 3.786

9.  Characterization of covalent modifications of HDL apoproteins by endogenous oxidized phospholipids.

Authors:  Detao Gao; Eugene A Podrez
Journal:  Free Radic Biol Med       Date:  2017-11-15       Impact factor: 7.376

10.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Authors:  Leonid Gaidukov; Dganit Bar; Shiri Yacobson; Esmira Naftali; Olga Kaufman; Rinat Tabakman; Dan S Tawfik; Etgar Levy-Nissenbaum
Journal:  BMC Clin Pharmacol       Date:  2009-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.